

Carbidopa-Levodopa Enteral Suspension



Included Products: Duopa (carbidopa-levodopa enteral suspension)

Nonformulary for outpatient benefit. PA required on medical benefit.

Created: 05/12/2022

Revised: 05/12/2022

Reviewed: 11/10/2022

Updated: 12/01/2022

Parkinson's Disease

Initial Criteria		If yes	If no
1.	Is Duopa prescribed by a neurologist?	Continue to #2.	Do not approve.
2.	Does the member have a diagnosis of advanced Parkinson's disease?	Continue to #3.	Do not approve.
3.	Is the member experiencing 3 or more hours of "off" time per day, such as sudden uncontrolled movements, muscle stiffness, slow movements, or difficulty starting movements?	Continue to #4.	Do not approve.
4.	Has member had a positive clinical response to oral levodopa?	Continue to #5.	Do not approve.
5.	Has the member had failure or intolerance of oral extended-release carbidopa/levodopa?	Continue to #6.	Do not approve.
6.	Has the member failed ALL other formulary oral treatments: entacapone, pramipexole, ropinirole, and selegiline?	Continue to #7.	Do not approve.
7.	Approve for 6 months.		
Renewal Criteria		If yes	If no
1.	Has the member had objective improvement in "off" time while using Duopa?	Continue to #2.	Do not approve.
2.	Approve for 12 months.		